E-platform M3 acquires majority share in Neuroglia Health Private Limited

Published On 2019-04-23 04:00 GMT   |   Update On 2021-08-17 05:28 GMT

New Delhi: An online platform for medical professionals, M3, Inc. of Japan has announced the acquisition of a majority stake of India based Neuroglia Health Private Limited (NHPL), a startup that provides web-based applications for Doctors and Medical students in India, for an undisclosed amount.


This move marks M3's foray into case-based problem-solving community platform and Medical test preparation business in India, in addition to its existing business Health Impetus Private limited (HIPL). HIPL (under the brand name of M3 India) currently runs Online portals that help Indian Doctors stay abreast with the latest in research, medical news, evidence-based medicine, practice guidelines and expert articles etc.


Commenting on the acquisition, Amit Singh, CEO of HIPL (M3 India) said, "With this majority acquisition, M3 India will now be able to reach out to 450,000 Doctors in India on a consolidated basis, while enhancing the utility and satisfaction levels among Doctors by leveraging the strengths of both platforms. It will also enable M3 India to escalate its marketing support and market research businesses to pharmaceutical and medical devices companies through an expansion of doctor membership and enhancement of medical education contents."


"We are very excited with this development. The Indian Doctor community is very active on DailyRounds and Marrow. With the support of M3, we will be offering better services to the existing Doctors. Further, we hope to bring in new Doctors as well. The goal is to be the largest Doctor network in India, not just by registered numbers, but in terms of active users as well." Dr Deepu Sebin, CEO of NHPL commented.


M3 also intends to import services and technologies developed in Japan and/or internationally into India, such as job placement support services and AI applications, with an aim to build next-generation healthcare technologies.


M3 operates m3.com, a specialized web portal for medical professionals that delivers healthcare-related information to its over 270,000 physician members in Japan and over 4.5 million physician members globally across multiple websites, to offer marketing, clinical trial, and various other services in healthcare and pharmaceutical industries. In India, M3 established its joint venture HIPL in August 2016 together with Health Care at Home India (HCAH).


Neuroglia Health Private Limited (NHPL) owns and operates "DailyRounds" Mobile App – a case-based problem-solving community platform for doctors in India, along with "Marrow" which is a test-preparation platform to enter post-graduate speciality courses in medical schools in India.


Also Read: Dr Reddy's expands injectable portfolio with acquisition of 42 ANDAs in US

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News